Cell Bio Human Tech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Cell Bio Human Tech makes the fabric sheet material used inside face mask packs, the thin, skin-adhering layer that holds skincare serum against the face.
It supplies this cellulose-based material to cosmetics manufacturers, and also produces hydrocolloid patch products used in cosmetic applications. Listed on KOSDAQ, Korea's tech and small-cap board, the company has expanded beyond its core mask-pack material into contract manufacturing of finished cosmetic products, including sheet masks, pads, and hydrogel mask packs.
Summary is AI-generated and may contain errors · figures from DART filings
The company was founded by a researcher from the Korea Institute of Industrial Technology, applying medical textile research to develop a domestically produced alternative to imported mask-pack materials.
Cell Bio Human Tech in five facts
What does Cell Bio Human Tech do?
Cell Bio Human Tech makes the fabric sheet material used inside face mask packs, the thin, skin-adhering layer that holds skincare serum against the face.
Where is Cell Bio Human Tech listed and in which sector?
Cell Bio Human Tech (Korean name: 셀바이오휴먼텍) trades under KRX code 318160 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Discretionary sector, Consumer Durables.
How large is Cell Bio Human Tech?
Its market capitalisation was US$45.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Cell Bio Human Tech's latest annual revenue and operating profit?
For fiscal year 2025, Cell Bio Human Tech reported revenue of US$38.5M, operating profit of US$7M and net income of US$6.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 79.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Treasury share trust terminated: results reportOct 21
- Material event report (treasury share trust terminated)Oct 21
- Treasury share acquisition via trust: status reportSep 11
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Cell Bio Human Tech reported consolidated results for FY2025: revenue of US$35M (+79.69% year on year), operating profit of US$6.44M (+132.63% year on year) and net income of US$5.6M (+86.51% year on year).
Earnings · Feb 10